In Vitro Safety

Leading the way with new study options rooted in the 3Rs

The world’s demand for safe products is growing, and the demand for innovative in vitro models is growing along with it. We have built a reputation for quickly and effectively responding to changing regulatory requirements as well as the evolving industry sentiments regarding product testing. Our researchers have a keen focus on bringing you more in in vitro alternatives and automation driven study solutions.

Novel Compounds Require Novel Approaches

As you progress in your development journey, let us be your partner. We offer custom in vitro assays and New Approach Methodologies (NAMs) with flexible design options and work with you to determine which mechanistic and biological endpoints are most relevant. Our scientists are at the cutting edge of in vitro alternative method development and are frequently requested to participate in regulatory working groups and testing/validation programs.

in vitro Safety Capabilities 

Cardiovascular Safety

• Ion channels (hERG, CaV1.2, NaV1.5 peak, NaV1.5 late)
• Human stem cell derived cardiomyocyte (action potential, contractility, intracellular calcium)

Cell Based Endocrine Disruptor Assays

• Estrogen receptor transactivation (in vitro assay)
• Androgen receptor transactivation (in vitro assay)
• Thyroid receptor transactivation (in vitro assay)
• Steroidogenesis (whole pathway in vitro assay)

in vitro Aerosol Testing

• Ames Assay - OECD 471 
  • Standard OECD battery strains
  • TA104 and YG strains
• NRU toxicity assay - modified method based on ICCVAM, 2006 protocol and OECD 129
  • CHO
  • Balb/c 3T3
  • NHBE
  • A549
  • H292
• IVM assay
• 3D tissue models
  • EpiAirway™ (Mattek), MucilAir™ (Epithelix), EpiOral™ (Mattek)
  • Endpoints – MTT, LDH, WST-8, Oxidative Stress
  • Supplementary endpoints – TEER, cilia beat frequency, mucociliary clearance, goblet cell hyperplasia, markers of apoptosis, cytokine release and RNA expression analysis

In vitro Alternatives 

• Local Tolerance
• Sensitisation
• Cytotoxicity and Phototoxicity
• Mechanistic / Mode of Action
• Carcinogenesis
• TruLarv

In vitro Inhalation

• Modified Genetic Toxicology Assays
• Cytotoxicity
• 2D and 3D Tissue Models

R&D and Bespoke Assay Solutions

• Custom in vitro assays
• Mechanistic/ MoA endpoints
• Biological endpoints
• AOP approaches
• Customised discovery projects

Explore more Drug Discovery capabilities or browse common capabilities in our catalog:

• Discovery Pharmacology
• Discovery DMPK
• Discovery Oncology